Alergologia Polska - Polish Journal of Allergology

Severe relapses of chronic spontaneous urticaria following omalizumab discontinuation

Katarzyna Skorek 1
,
Marek Przybyszowski 1, 2
,
Grażyna Bochenek 1, 2
,
Krzysztof Sładek 1, 2

  1. Department of Pulmonology, Allergology, and Internal Medicine, University Hospital, Krakow, Poland

  2. Second Department of Internal Medicine, Department of Pulmonology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland

Alergologia Polska – Polish Journal of Allergology

DOI: https://doi.org/10.5114/pja.2026.163798
Data publikacji online: 2026/08/03
Article file
PJA Severe.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Barzilai A, Baum A, Ben-Shoshan M, et al. Epidemiological and clinical characteristics of adult and pediatric patients with chronic spontaneous urticaria. J Clin Med 2023; 12: 7482.
  2. Sussman G, Hébert J, Gulliver W, et al. Insights and advances in chronic urticaria: a Canadian perspective. Allergy Asthma Clin Immunol 2015; 11: 7.
  3. Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy 2017; 72: 2005-16.
  4. Itakura A, Tani Y, Kaneko N, Hide M. Impact of chronic urticaria on quality of life and work in Japan: results of a real-world study. J Dermatol 2018; 45: 963-70.
  5. Bulkhi AA. Beyond antihistamines: how biologic and small-molecule therapies are transforming chronic spontaneous urticaria care in adults. Clin Drug Investig 2025; 45: 743-66.
  6. Ministerstwo Zdrowia. Program lekowy: leczenie chorych z przewlekłą pokrzywką spontaniczną (ICD-10: L50.1, L50.8, L50.9) [Internet]. Warszawa: Ministerstwo Zdrowia; 2024 [cited 2025 Dec 22]. Available from: dziennikmz.mz.gov.pl
  7. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022; 77: 734-66.
  8. Ceravalls J, Giménez-Arnau AM, Expósito-Serrano V, et al. Redefining omalizumab withdrawal in patients with chronic spontaneous urticaria: the value of optimisation and biomarkers of recurrence. Actas Dermosifiliogr 2025; 116: T675-83.
  9. Sağun F, Çölkesen F, Gerek ME, et al. Clinical and laboratory predictors of relapse within one year after omalizumab discontinuation in chronic spontaneous urticaria: a real-life cohort study. Int Arch Allergy Immunol 2025; 18: 1-9.
  10. Metz M, Ohanyan T, Church MK, et al. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol 2014; 150: 288-90.
  11. Brás R, Costa C, Limão R, et al. Omalizumab in chronic spontaneous urticaria: real-life experience in dose/interval adjustments and treatment discontinuation. J Allergy Clin Immunol Pract 2023; 11: 2392-402.
  12. Kucharczyk A, Marczyk K, Kucharczyk B, et al. Predicting relapse in chronic spontaneous urticaria: a retrospective cohort study valuating omalizumab withdrawal regimens. Allergy 2024; 79: 2554-7.
  13. Üstün P, Adışen E. factors influencing relapse after omalizumab in chronic urticaria. does the method of discontinuation influence relapse? Dermatol Pract Concept 2025; 15: 5196.
  14. Üstün P, Adışen E. Factors influencing relapse after omalizumab in chronic urticaria: does the method of discontinuation influence relapse? Dermatol Pract Concept 2025; 15: 5196.
  15. Mateu-Arrom L, Vence Nogueira XA, Puig L, Spertino J. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a narrative review focusing on parameters available in routine clinical practice. Front Allergy 2025; 6: 1688464.
  16. Vollono L, Piccolo A, Lanna C, et al. Omalizumab for chronic spontaneous urticaria in complex patients: data from real-life clinical practice. Drug Des Devel Ther 2019; 13: 3181-6.
  17. Lesiak A, Bień N, Lipińska K, et al. The effectiveness of omalizumab therapy in patients with chronic spontaneous urticaria: the experience of a single-centre study in Poland. Adv Dermatol Allergol 2024; 41: 301-5.
  18. Alizadeh Aghdam M, Pieterse RH, Kentie PA, et al. Effective omalizumab interval prolongation in the treatment of chronic urticaria. J Allergy Clin Immunol Pract 2020; 8: 3667-8.e1.
  19. Zhang DG, Sørensen JA, Ghazanfar MN, et al. EXtending Omalizumab Treatment Intervals in patients with Chronic spontaneous urticaria (EXOTIC): protocol of a multicentre, randomised, open-label, non-inferiority trial. BMJ Open 2025; 15: e084987.
Copyright: © Polish Society of Allergology This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivatives 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Coverage in
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications